Indexed In
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- ResearchBible
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Proquest Summons
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- MIAR
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.
Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
30 | 56 | 30 | 30 | 13 | 4 | 7 | 15 | 13 | 20 | 25 | 12 | 35 | 13 | 2 |
Research, Review articles and Editorials |
0 | 6 | 2 | 4 | 1 | 1 | 6 | 14 | 12 | 17 | 25 | 12 | 34 | 7 | 2 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
30 | 50 | 28 | 8 | 2 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 | 0 | 35 | 102 | 83 | 47 | 82 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
35 | 55 | 58 | 71 | 61 | 49 | 63 | 48 | 72 | 63 | 23 | 8 | 6 | 0 | 0 |
| Journal total citations count | 613 |
| Journal impact factor | 2.31 |
| Journal 5 years impact factor | 3.74 |
| Journal cite score | 4.86 |
| Journal h-index | 12 |
Important citations
Tremaine L, Brian W, DelMonte T, Francke S, Groenen P, et.al (2015) The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Pharmacogenomics 16: 2055-2067.
Bitto A, Pallio G, Messina S, Arcoraci V, Pizzino G, et.al (2016) Genomic Variations Affecting Biological Effects of Statins. Current drug metabolism 17: 566-572.
Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, et.al (2015) Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. Journal of cardiovascular pharmacology 66: 80.
Stegemann S (2016) The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution. European Journal of Pharmaceutical Sciences 90: 8-13.
Hess GP, Fonseca E, Scott R, Fagerness J (2015) Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genetics research 97: e13.
HubáÄek JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, et.al (2015) SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Medical Science Monitor 21:1454- 1459.
P Agouridis A, S Elisaf M, R Nair D, P Mikhailidis D (2016) All for statins and statins for all; an update. Current pharmaceutical design 22: 18-27.
Huang Q, Aa J, Jia H, Xin X, Tao C, et.al (2015) A pharmacometabonomic approach to predicting metabolic phenotypes and pharmacokinetic parameters of atorvastatin in healthy volunteers. Journal of proteome research 14: 3970-3981.
Сихаева ÐС, ИÑкакова ÐÐ, Ðйткулова ÐÐœ, Жолдыбаева ЕВ, Момыналиев КТ, Раманкулов ЕМ. ЧÐСТОТРВСТРЕЧÐЕМОСТИ 19 ÐЛЛЕЛЬÐЫХ ПОЛИМОРФИЗМОВ Ð’ КÐЗÐХСКОЙ ПОПУЛЯЦИИ. БиотехнологиÑ. 2014(3):4-11.
Azarara M, Afrasibirad A, Farzamikia N, Alijani A, Sakhinia E (2016) The effect of GGCX and CYP4F2 gene polymorphisms in genotype-guided dosing of warfarin in patients with a history of cardiac surgery. Journal of Pharmaceutical Investigation 1-7.
Huang TS, Zhang L, He Q, Li YB, Dai ZL, et.al (2017) DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation. Australasian Physical & Engineering Sciences in Medicine1-0.
Iskakova AN, Romanova AA, Aitkulova AM, Sikhayeva NS, Zholdybayeva EV,et.al (2016) Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. BMC genetics 17: 23.
Sultana S (2014) Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences.
Bhat IA, Pandith AA, Yaqoob I, Faheem S, Hafeez I, et.al (2015) Genetic Determinants of CYP2C19 Gene* 2 and* 3 Loss of Function Alleles and Response to Anti Platelet Therapy (Clopidogrel) and Cardiovascular Events.(A Study in Kashmir, North India). Biology and Medicine 7: 1.
Teixeira J, Amorim A, J Prata M, Quental S (2015) Pharmacogenetic Polymorphisms in a Portuguese Gypsy Population. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) 13: 36-40.
Sultana S (2016) Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences.
Cacabelos R (2016) Metabolomics: Open Access.
Singh BM, Mohanvir K, Nishit G, Kumar BV (2015) RESEARCH AND REVIEWS: JOURNAL OF MEDICAL AND HEALTH SCIENCES.
Cacabelos R, Teijido O, Carril JC. Can cloud-based tools accelerate Alzheimer’s disease drug discovery?.
ÐлекÑн БГ, Ðбугов СÐ, Ðндреев ДÐ, БурÑчковÑÐºÐ°Ñ Ð›Ð˜, Вавилова ТВ, Вершинина МГ, Воробьева ÐÐ, Иванова ГЕ, Ломакин ÐÐ’, Мешкова КС, ПокровÑкий ÐÐ’ (2014) Роль теÑÑ‚Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ñ Ñ„ÑƒÐ½ÐºÑ†Ð¸Ð¾Ð½Ð°Ð»ÑŒÐ½Ð¾Ð¹ активноÑти тромбоцитов в профилактике Ñердечно-ÑоÑудиÑÑ‚Ñ‹Ñ… оÑложнений у больных, получающих антитромбоцитарную терапию. Ð Ð°Ñ†Ð¸Ð¾Ð½Ð°Ð»ÑŒÐ½Ð°Ñ Ñ„Ð°Ñ€Ð¼Ð°ÐºÐ¾Ñ‚ÐµÑ€Ð°Ð¿Ð¸Ñ Ð² кардиологии 10(6).